Unicycive Therapeutics, Inc. SEC filings UNCY
Unicycive Therapeutics, Inc. has 307 filings in SEC EDGAR's recent list, going back to Mar 4, 2019. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jun 15, 2026 | — |
| CORRESP | Letter to the SEC | Jun 11, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 11, 2026 | — |
| EFFECT | Filing | Nov 20, 2024 | — |
| CORRESP | Letter to the SEC | Nov 18, 2024 | — |
| EFFECT | Filing | Nov 14, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2024 | — |
| EFFECT | Filing | Jul 16, 2024 | — |
| CORRESP | Letter to the SEC | Jul 11, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2024 | — |
| D | Filing | Mar 20, 2024 | — |
| EFFECT | Filing | Aug 3, 2023 | — |
| CORRESP | Letter to the SEC | Aug 1, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 19, 2023 | — |
| NT 10-Q | Notification of late filing | May 16, 2023 | Mar 31, 2023 |
| D | Filing | Mar 13, 2023 | — |
| EFFECT | Filing | Aug 24, 2022 | — |
| CORRESP | Letter to the SEC | Aug 22, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 22, 2022 | — |
| SEC STAFF LETTER | Filing | Jul 21, 2021 | — |
| EFFECT | Filing | Jul 12, 2021 | — |
| CORRESP | Letter to the SEC | Jul 8, 2021 | — |
| CORRESP | Letter to the SEC | Jul 8, 2021 | — |
| CORRESP | Letter to the SEC | Jul 7, 2021 | — |
| CERT | 8a cert | Jul 7, 2021 | — |
| 8-A12B | Filing | Jul 6, 2021 | — |
| CORRESP | Letter to the SEC | Jul 6, 2021 | — |
| CORRESP | Letter to the SEC | Jul 6, 2021 | — |
| CORRESP | Letter to the SEC | Jun 23, 2021 | — |
| CORRESP | Letter to the SEC | Jun 22, 2021 | — |
| CORRESP | Letter to the SEC | Jun 14, 2021 | — |
| CORRESP | Letter to the SEC | Jun 14, 2021 | — |
| SEC STAFF LETTER | Filing | Jun 7, 2021 | — |
| CORRESP | Letter to the SEC | Jun 7, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2021 | — |
| CORRESP | Letter to the SEC | May 21, 2021 | — |
| UPLOAD | Letter from the SEC | May 10, 2021 | — |
| DRS/A | Filing | Apr 29, 2021 | — |
| DRSLTR | Filing | Apr 29, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 17, 2021 | — |
| DRS/A | Filing | Feb 18, 2021 | — |
| DRSLTR | Filing | Feb 18, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 10, 2020 | — |
| DRS/A | Filing | Nov 2, 2020 | — |
| DRSLTR | Filing | Oct 30, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 9, 2020 | — |
| DRSLTR | Filing | Sep 15, 2020 | — |
| DRS | Filing | Sep 15, 2020 | — |
| D | Filing | Jun 3, 2020 | — |
| D | Filing | Aug 16, 2019 | — |
| D | Filing | Mar 4, 2019 | — |
Showing 51 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UNCY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1766140
- Former names
- Unicycive Therapeutics, Inc. (until Oct 29, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.